🇺🇸 FDA
Pipeline program

Gazyvaro 1,000 mg concentrate for solution for infusion.

APHP211000

Phase 2 small_molecule active

Quick answer

Gazyvaro 1,000 mg concentrate for solution for infusion. for PR3-ANCA granulomatosis with polyangiitis (Wegener’s) is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
PR3-ANCA granulomatosis with polyangiitis (Wegener’s)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials